Data / Form D filings / Claris Biotherapeutics, Inc.
Claris Biotherapeutics, Inc.: Form D filings
Claris Biotherapeutics, Inc., a biotechnology company in Half Moon Bay, CA, filed 8 Form D notices with the SEC between 2020 and 2026. The latest, on August 12, 2026, reports $55.7 million sold of a $121.5 million offering to 14 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 475 MAGELLAN AVE, Half Moon Bay, CA, 94019
- Phone
- (201) 344-7638
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1809726
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Amendment | $121,477,910 | $55,737,646 | $65,740,264 | 14 | Nov 25, 2025 | sec.gov |
| Aug 7, 2026 | New notice | $121,477,910 | $55,737,646 | $65,740,264 | 14 | Nov 25, 2025 | sec.gov |
| Sep 22, 2025 | New notice | $2,300,000 | $2,300,000 | 6 | Sep 12, 2025 | sec.gov | |
| Mar 7, 2025 | New notice | $3,300,000 | $3,299,999 | $1 | 6 | Feb 26, 2025 | sec.gov |
| Jan 8, 2024 | New notice | $9,999,998 | $9,999,998 | 3 | Dec 28, 2023 | sec.gov | |
| Oct 24, 2023 | Amendment | $44,499,994 | $44,499,994 | 6 | Apr 13, 2020 | sec.gov | |
| Jul 14, 2021 | Amendment | $38,499,996 | $38,499,996 | 6 | Apr 13, 2020 | sec.gov | |
| Apr 27, 2020 | New notice | $25,999,999 | $11,846,938 | $14,153,061 | 1 | Apr 13, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Stephen Brady | Executive Officer, Director | |
| Reza Dana | Director | |
| Kenneth Harrison | Director | |
| Marc de Garidel | Director | |
| Meredith Fisher | Director | |
| Henry Rath | Executive Officer | |
| Susan Orr | Executive Officer | |
| Michael Dybbs | Director | |
| Matt Hobson | Director | |
| Maha Radhakrishnan | Director | |
| Clarke Atwell | Executive Officer | |
| Brian Baum | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 10, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Claris Biotherapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.